Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase

Class

broad-spectrum anticonvulsant; sulfamate-substituted fructopyranose derivative; multi-mechanism agent

Pathway

blocks voltage-dependent sodium channels in a state-dependent manner, augments GABA-A receptor-mediated chloride currents at certain receptor subtypes, antagonizes the AMPA/kainate subtype of the glutamate receptor, and weakly inhibits carbonic anhydrase isozymes II and IV; the FDA label states the precise mechanism underlying its antiepileptic and migraine-preventive effects is not fully understood

This mechanism describes a multi-target anticonvulsant that acts on several distinct neuronal signaling systems rather than a single receptor or channel. It blocks voltage-gated sodium channels in a state-dependent manner, meaning it preferentially binds channels that are already open or inactivated, which limits its action to neurons firing abnormally fast without broadly suppressing normal signaling. It also enhances the inhibitory neurotransmitter GABA's effect at certain GABA-A receptor subtypes, increasing chloride ion flow into neurons and making them less excitable, while separately blocking AMPA/kainate receptors, which normally respond to the excitatory neurotransmitter glutamate. A weak inhibition of carbonic anhydrase, an enzyme involved in acid-base and fluid regulation, contributes additional but less central effects. The rationale for combining these mechanisms in one molecule is that seizures and related hyperexcitability disorders can arise from multiple points of dysregulation—excessive excitatory drive, insufficient inhibitory tone, or channel hyperactivity—so an agent acting at several nodes may control neuronal firing more broadly than a single-mechanism drug. This profile is relevant across epilepsy syndromes and in migraine prevention, where circuit-level neuronal excitability is thought to play a role, illustrating how one compound can be positioned across neurological indications with overlapping excitability pathophysiology.